Author:
ter Welle-Butalid M. E. (Elena),Vriens I. J. H. (Ingeborg),Derhaag J. G. (Josien),Leter E. M. (Edward),de Die-Smulders C. E. (Christine),Smidt M. (Marjolein),van Golde R. J. T. (Ron),Tjan-Heijnen V. C. G. (Vivianne)
Abstract
Abstract
Purpose
Women with early-stage breast cancer may still have a future child wish, while chemotherapy may impair fertility. To pursue on fertility preservation shortly after breast cancer diagnosis is complex. This review holds a critical reflection on all topics that need to be counseled to give them the opportunity to make a well-informed decision before starting any oncological treatment.
Methods
A comprehensive literature review was performed on papers published in English language on breast cancer in young women, risk of chemotherapy-induced infertility, fertility preservation techniques, impact of possible mutation carriership, and future pregnancy outcome.
Results
Below 40 years of age, the risk of permanent chemotherapy-induced ovarian function failure is approximately 20%, where taxanes do not significantly add to this risk. Overall, 23% of reported women who performed fertility preservation by cryopreserving oocytes or embryos returned for embryo transfer. Of these, 40% gave live birth. Both fertility preservation in women diagnosed with breast cancer and pregnancy after treatment seem safe with respect to breast cancer survival. Women who have a genetic predisposition for breast cancer like BRCA gene mutation should also be informed about the possibility of pre-implantation genetic diagnosis.
Conclusions
Women with an early stage of breast cancer and a possible future child wish should be referred to an expertise center in breast cancer, fertility preservation, and genetics in this complex decision-making process, shortly after diagnosis.
Funder
Maastricht University Medical Center
Publisher
Springer Science and Business Media LLC
Subject
Genetics(clinical),Developmental Biology,Obstetrics and Gynaecology,Genetics,Reproductive Medicine,General Medicine
Reference107 articles.
1. Ferlay L, Soerjomataram I, Ervik M. Cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer (GLOBOCAN), 2012. http://globocan.iarc.fr. Accessed 11 March 2017.
2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30. https://doi.org/10.1200/JCO.2007.14.2471.
3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365(9472):1687–717. https://doi.org/10.1016/s0140-6736(05)66544-0.
4. Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early-stage breast cancer. Fertil Steril. 2010;94(2):638–44. https://doi.org/10.1016/j.fertnstert.2009.03.045.
5. Mathews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献